Results 41 to 50 of about 46,179 (165)

Left Ventricular Regional Wall Motion Abnormality is a Strong Predictor of Cardiotoxicity in Breast Cancer Patients Undergoing Chemotherapy

Arquivos Brasileiros de Cardiologia, 2018
Background: Chemotherapeutic agents of anthracyclines class and humanized monoclonal antibodies are effective treatments for breast cancer, however, they present a potential risk of cardiotoxicity. Several predictors have been recognized as predictors in
Márcio Vinícius Lins de Barros, Ariane Vieira Scarlatelli Macedo, Sebastian Imre Sarvari, Monica Hermont Faleiros, Patricia Tavares Felipe, Jose Luiz Padilha Silva, Thor Edvardsen   +6 more
doaj   +1 more source

Cardiac Morbidity and Mortality in Patients with Sarcoma: A Population-Based Study

Clinical Medicine Insights: Oncology
Background: Soft tissue sarcoma (STS) is a rare malignancy that affects soft tissues. It encompasses various subtypes and requires different treatment strategies.
Rakan Alanazi, Ahmed Aljizeeri, Ahmed Alsaileek, Azzam Alrashid, Ashwaq Alolayan, Mohammad Alkaiyat, Basel Alenazy, Hussam Shehata, Joud Alqahtani, Husam Ardah, Kanan Alshammari   +10 more
doaj   +1 more source

Melphalan induces cardiotoxicity through oxidative stress in cardiomyocytes derived from human induced pluripotent stem cells

Stem Cell Research & Therapy, 2020
Background Treatment-induced cardiotoxicity is a leading noncancer-related cause of acute and late onset morbidity and mortality in cancer patients on antineoplastic drugs such as melphalan—increasing clinical case reports have documented that it could ...
Rui Liu, Dong Li, Fangxu Sun, Antonio Rampoldi, Joshua T. Maxwell, Ronghu Wu, Peter Fischbach, Sharon M. Castellino, Yuhong Du, Haian Fu, Anant Mandawat, Chunhui Xu   +11 more
doaj   +1 more source

Methylation-based biological age and cardiotoxicity risk in breast cancer patients treated with trastuzumab

Cardio-Oncology
Background Trastuzumab is an effective treatment for HER2-positive cancers that has known cardiotoxic properties. Discovering biomarkers that assess cardiotoxicity risk before trastuzumab therapy is essential for protecting the cardiovascular health of ...
Jamila Mammadova, Alicia Richards, Adriana Gonzalez-Torriente, Evan R. Adler, Rachel J. Cruz, Stefanie Palfi, Dae Hyun Lee, Christine Sam, Mohammed Al-Jumayli, Anders Berglund, Jong Y Park, Mohammed Alomar, Jacob K. Kresovich   +12 more
doaj   +1 more source

Sarmentosin alleviates doxorubicin-induced cardiotoxicity and ferroptosis via the p62-Keap1-Nrf2 pathway

Redox Report
Doxorubicin (Dox) is extensively used as an antitumor agent, but its severe cardiotoxicity significantly limits its clinical use. Current treatments for Dox-induced cardiotoxicity are inadequate, necessitating alternative solutions.
Zhihui Lin, Chang Wu, Dongyan Song, Chenxi Zhu, Bosen Wu, Jie Wang, Yangjing Xue   +6 more
doaj   +1 more source

Potential role of endoplasmic reticulum stress in doxorubicin-induced cardiotoxicity-an update

Frontiers in Pharmacology
As a chemotherapy agent, doxorubicin is used to combat cancer. However, cardiotoxicity has limited its use. The existing strategies fail to eliminate doxorubicin-induced cardiotoxicity, and an in-depth exploration of its pathogenesis is in urgent need to
Mingli Sun, Xin Zhang, Boxuan Tan, Qingya Zhang, Xiaopeng Zhao, Dan Dong   +5 more
doaj   +1 more source

Mitochondria-Targeting Small Molecules Effectively Prevent Cardiotoxicity Induced by Doxorubicin

Molecules, 2018
Doxorubicin (Dox) is a chemotherapeutic agent widely used for the treatment of numerous cancers. However, the clinical use of Dox is limited by its unwanted cardiotoxicity. Mitochondrial dysfunction has been associated with Dox-induced cardiotoxicity. To
Wei Shi, Hongkuan Deng, Jianyong Zhang, Ying Zhang, Xiufang Zhang, Guozhen Cui   +5 more
doaj   +1 more source

PICALM Regulating the Generation of Amyloid β‐Peptide to Promote Anthracycline‐Induced Cardiotoxicity

Advanced Science
Anthracyclines are chemotherapeutic drugs used to treat solid and hematologic malignancies. However, life‐threatening cardiotoxicity, with cardiac dilation and heart failure, is a drawback.
Mengni Bao, Xiumeng Hua, Xiao Chen, Tao An, Han Mo, Zhe Sun, Menghao Tao, Guangxin Yue, Jiangping Song   +8 more
doaj   +1 more source

5-Fluorouracil-induced cardiotoxicity mimicking myocardial infarction: a case report

BMC Cardiovascular Disorders, 2001
Background Severe cardiotoxicity is a documented, but very unusual side-effect of intravenous 5-fluorouracil therapy. The mechanism producing cardiotoxicity is poorly understood. Case presentation A case of 5-fluorouracil-induced cardiotoxicity, possibly
Campbell Norman PS, Webb Stephen T, McGlinchey Paul G   +2 more
doaj   +1 more source

The association between systemic immune-inflammation index and cardiotoxicity related to 5-Fluorouracil in colorectal cancer

BMC Cancer
Background and aims The cardiotoxicity related to 5-Fluorouracil (5-FU) in cancer patients has garnered widespread attention. The systemic immune-inflammation index (SII) has recently been identified as a novel predictive marker for the development of ...
Xiaoqin Liu, Yan Wang, Wenling Wang, Hongming Dong, Gang Wang, Wanghua Chen, Juan Chen, Weiwei Chen   +7 more
doaj   +1 more source